OREANDA-NEWS. August 25, 2010. JSC “Grindeks” informs that a senior management meeting of “Grindeks” and the Latvian Institute of Organic Synthesis (IOS) took place, during which both sides agreed on closer cooperation in new product development.

During the meeting issues on development and initiation of commercialization process of various patent-protected and generic products were overviewed, as well as an agreement on the involvement of IOS in the clinical trial program of Mildronate® in China was reached.

Chairman of the Council of the JSC “Grindeks” Kirovs Lipmans: “Combining international experience of “Grindeks” in the pharmaceutical sector and the high scientific potential of IOS, we have jointly agreed on closer cooperation. The biggest benefit for “Grindeks” will be new, promising and effective medicines.”

Director of the Latvian Institute of Organic Synthesis Ivars Kalvins: “The meeting was fruitful - development and potential scenarios of implementation and registration of new original as well as generic medications were discussed. We have mutually agreed on both the areas of cooperation, and also on concrete action plan and deadlines.”